Tag Archives: GTXI

Top 10 Performing Stocks To Buy For 2019

March 10, 2017: Markets opened higher Friday following another month of strong non-farm payroll gains. Top performing sectors today were industrials, telecoms, and utilities. The weakest performer was real-estate. WTI crude oil for April delivery settled at $48.49 a barrel, down 1.6% on the day and down more than 9% for the week. April gold dropped 0.2% on the day to settle at $1,201.40. Equities were headed for a higher close shortly before the bell as the DJIA traded up 0.20% for the day, the S&P 500 traded up 0.28%, and the Nasdaq Composite traded up 0.35%.

The DJIA stock posting the largest daily percentage gain ahead of the close Friday was General Electric Co. (NYSE: GE) which traded up 2.14% at $30.30. The stock’s 52-week range is $28.19 to $33.00. Shares got a boost on a report that CEO Jeff Immelt is being pushed to retire.

UnitedHealth Group Inc. (NYSE: UNH) traded up 1.11% at $169.87. The stock’s 52-week range is $122.22 to $3170.00, a new high posted this afternoon. Volume was about 30% below the daily average of around 3.5 million shares. The company had no specific news Friday.

Top 10 Performing Stocks To Buy For 2019: ARMOUR Residential REIT, Inc.(ARR)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ARMOUR Residential REIT (NYSE:ARR) was the target of some unusual options trading activity on Thursday. Stock traders acquired 657 call options on the stock. This represents an increase of approximately 1,163% compared to the typical volume of 52 call options.

Top 10 Performing Stocks To Buy For 2019: Jazz Pharmaceuticals Inc.(JAZZ)

Advisors’ Opinion:

  • [By Lee Jackson]

    This top company is a favorite across Wall Street.Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is a biopharmaceutical company that identifies, develops and commercializes pharmaceutical products for various medical needs in the United States, Europe and elsewhere. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

  • [By Logan Wallace]

    Swiss National Bank trimmed its holdings in shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) by 13.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 192,000 shares of the specialty pharmaceutical company’s stock after selling 29,100 shares during the quarter. Swiss National Bank owned 0.32% of Jazz Pharmaceuticals worth $28,990,000 at the end of the most recent reporting period.

  • [By Lisa Levin]

     

    Companies Reporting After The Bell
    Marriott International, Inc. (NASDAQ: MAR) is projected to post quarterly earnings at $1.22 per share on revenue of $5.72 billion.
    Electronic Arts Inc. (NASDAQ: EA) is estimated to post quarterly earnings at $1.04 per share on revenue of $5.68 billion.
    The Walt Disney Company (NYSE: DIS) is projected to post quarterly earnings at $1.68 per share on revenue of $14.05 billion.
    Papa John's International, Inc. (NASDAQ: PZZA) is expected to post quarterly earnings at $0.62 per share on revenue of $441.73 million.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is projected to post quarterly earnings at $2.77 per share on revenue of $434.87 million.
    Sun Life Financial Inc. (NYSE: SLF) is estimated to post quarterly earnings at $0.89 per share on revenue of $6.38 billion.
    LATAM Airlines Group S.A. (NYSE: LTM) is expected to post quarterly earnings at $0.16 per share on revenue of $2.70 billion.
    Liberty Global plc (NASDAQ: LBTYA) is projected to post quarterly earnings at $0.02 per share on revenue of $4.05 billion.
    TripAdvisor, Inc. (NASDAQ: TRIP) is expected to post quarterly earnings at $0.16 per share on revenue of $362.11 million.
    The Wendy's Company (NASDAQ: WEN) is projected to post quarterly earnings at $0.1 per share on revenue of $379.98 million.
    A-Mark Precious Metals, Inc. (NASDAQ: AMRK) is expected to post quarterly earnings at $0.06 per share on revenue of $1.69 billion.
    Monster Beverage Corporation (NASDAQ: MNST) is estimated to post quarterly earnings at $0.4 per share on revenue of $849.38 million.
    Convergys Corporation (NYSE: CVG) is expected to post quarterly earnings at $0.4 per share on revenue of $670.10 million.
    ScanSource, Inc. (NASDAQ: SCSC) is projected to post quarterly earnings at $0.7 per share on revenue of $875.91 million.
    KAR Auction Services, Inc. (NYSE: KAR) is expected to post quarterly earnings at $0.76 per share on revenue of $923.13

Top 10 Performing Stocks To Buy For 2019: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Logan Wallace]

    Valeant Pharmaceuticals International Inc (NYSE:VRX) (TSE:VRX) – Analysts at Jefferies Group reduced their Q3 2018 earnings per share (EPS) estimates for shares of Valeant Pharmaceuticals International in a research report issued to clients and investors on Tuesday, May 8th. Jefferies Group analyst D. Steinberg now anticipates that the specialty pharmaceutical company will earn $0.70 per share for the quarter, down from their prior forecast of $0.73. Jefferies Group currently has a “Buy” rating and a $23.00 target price on the stock. Jefferies Group also issued estimates for Valeant Pharmaceuticals International’s Q4 2018 earnings at $0.71 EPS and FY2022 earnings at $5.50 EPS.

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares rose 14.1 percent to $3.65 in the pre-market trading session after reporting 2017 year-end results.
    LightPath Technologies, Inc. (NASDAQ: LPTH) rose 13.3 percent to $2.43 in pre-market trading after reporting a third-quarter earnings beat.
    MYnd Analytics, Inc. (NASDAQ: MYND) rose 10.5 percent to $3.49 in pre-market trading. MYnd Analytics reported a Q2 net loss of $2.7 million on revenue of $459,900.
    SORL Auto Parts, Inc. (NASDAQ: SORL) shares rose 8.4 percent to $5.68 in pre-market trading after reporting upbeat Q1 results.
    Famous Dave's of America, Inc. (NASDAQ: DAVE) shares rose 7.7 percent to $8.40 in pre-market trading after the company reported upbeat earnings for its first quarter on Monday.
    Xenon Pharmaceuticals Inc. (NASDAQ: XENE) rose 7.5 percent to $6.45 in pre-market trading after the company presented XEN901 Phase 1 clinical update and XEN1101 TMS pharmacodynamic Phase 1 data.
    Mimecast Ltd (NASDAQ: MIME) rose 6.5 percent to $43.50 in pre-market trading following a first-quarter sales beat.
    Boxlight Corporation (NASDAQ: BOXL) rose 6 percent to $12.50 in pre-market trading after surging 77.44 percent on Monday.
    Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares rose 6 percent to $26.05 in pre-market trading after climbing 3.58 percent on Monday.
    PPDAI Group Inc. (NASDAQ: PPDF) rose 4.7 percent to $7.20 in pre-market trading following Q1 results.
    Xunlei Limited (NASDAQ: XNET) rose 4.1 percent to $13.88 in pre-market trading after gaining 2.54 percent on Monday.
    Valeant Pharmaceuticals International, Inc. (NYSE: VRX) shares rose 4.5 percent to $21.73 in pre-market trading. Mizuho upgraded Valeant from Neutral to Buy.
    Bovie Medical Corporation (NYSE: BVX) rose 4.1 percent to $3.80 in pre-market trading after reporting a first-quarter sales beat.
    Myomo, Inc. (NYSE: MYO) rose 3.4 percent to $4.00 in pre-market trading after jumping 23.25 percent o
  • [By Lee Jackson]

    This company has been fighting its way back now for over a year and may be a very solid contrarian play. Valeant Pharmaceuticals International Inc. (NYSE: VRX) operates as a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a range of pharmaceuticals, over-the-counter (OTC) products and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx and U.S. Diversified Products.

  • [By ]

    Sometimes it’s better to raise funds when you can vs. when you have to. Look no farther than Valeant Pharmaceuticals (VRX) , which is in a massive hole of debt and trades below $20 per share. It sure would have been nice to raise capital in a secondary offering with the stock over $200 per share for six months throughout 2015. 

  • [By Chris Lange]

    Valeant Pharmaceuticals International Inc. (NYSE: VRX) released its most recent quarterly report before the markets opened on Tuesday. At the same time, the firm announced that it would also be changing its name sometime in the very near future.

  • [By Dan Caplinger]

    The stock market finally hit some resistance on Tuesday, giving up ground and breaking a long streak of consecutive advances for most major benchmarks. Market participants got spooked by a rise in interest rates, with 10-year Treasury yields once again climbing above the 3% mark and leading some to predict even steeper advances in the future. With budget deficits ballooning, higher interest expenses on the national debt could have a dramatic impact on the U.S. economy, especially if it lures investors away from high-flying stocks. Yet even amid the bond-driven downturn, some individual companies saw good news lift their shares. Valeant Pharmaceuticals International (NYSE:VRX), Hollysys Automation Technologies (NASDAQ:HOLI), and Ascena Retail Group (NASDAQ:ASNA) were among the best performers on the day. Here’s why they did so well.

Top 10 Performing Stocks To Buy For 2019: Boot Barn Holdings, Inc.(BOOT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Macy's, Inc. (NYSE: M) to report quarterly earnings at $0.35 per share on revenue of $5.39 billion before the opening bell. Macy's shares fell 0.47 percent to $29.79 in after-hours trading.
    Analysts are expecting Cisco Systems, Inc. (NASDAQ: CSCO) to have earned $0.65 per share on revenue of $12.43 billion in the latest quarter. Cisco will release earnings after the markets close. Cisco shares declined 0.07 percent to $45.45 in after-hours trading.
    Boot Barn Holdings Inc (NYSE: BOOT) reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance. Boot Barn shares climbed 9.97 percent to $24.15 in the after-hours trading session.
    After the markets close, Flowers Foods, Inc. (NYSE: FLO) is projected to post quarterly earnings at $0.31 per share on revenue of $1.20 billion. Flowers Foods shares dropped 0.37 percent to $21.70 in after-hours trading.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Lisa Levin] Gainers
    Blink Charging Co. (NASDAQ: BLNK) shares jumped 26.5 percent to $6.9042. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares climbed 17.4 percent to $3.11. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    Flanigan's Enterprises, Inc. (NYSE: BDL) shares jumped 17 percent to $27.97 following Q2 results. Flanigan's Enterprises posted Q2 earnings of $0.75 per share on sales of $29.456 million.
    Borqs Technologies, Inc. (NASDAQ: BRQS) rose 15.8 percent to $8.05 after reporting Q1 results.
    Abaxis, Inc. (NASDAQ: ABAX) jumped 15.3 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    21Vianet Group, Inc. (NASDAQ: VNET) gained 15.1 percent to $6.33.
    Gemphire Therapeutics Inc. (NASDAQ: GEMP) rose 13.8 percent to $6.27.
    Enphase Energy, Inc. (NASDAQ: ENPH) gained 12.8 percent to $5.98. H.C. Wainwright initiated coverage on Enphase Energy with a Buy rating.
    PetIQ Inc (NASDAQ: PETQ) shares surged 12.1 percent to $21.68 after reporting a first-quarter sales beat.
    NF Energy Saving Corporation (NASDAQ: NFEC) climbed 11.6 percent to $2.399.
    Allied Healthcare Products, Inc. (NASDAQ: AHPI) surged 11.4 percent to $3.0643.
    Boot Barn Holdings, Inc. (NYSE: BOOT) gained 11.1 percent to $24.40 after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Ascena Retail Group, Inc. (NASDAQ: ASNA) rose 10.9 percent to $3.16.
    Sea Limited (NYSE: SE) gained 10.1 percent to $11.71 after reporting Q1 results.
    GEE Group, Inc. (NYSE: JOB) climbed 7.9 percent to $2.61 following Q2 results.
    The ONE Group Hospitality, Inc. (NASDAQ: STKS) gained 7.6 percent to $2.41 after reporting Q1 results.
    Biolinerx Ltd/S ADR (NASDAQ: BLRX) rose 7.3 percent to $0.8798 after the company was granted a patent approval. The clinical-st
  • [By Lisa Levin]

    Shares of Boot Barn Holdings, Inc. (NYSE: BOOT) got a boost, shooting up 13 percent to $24.815 after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.

  • [By Lisa Levin] Gainers
    Blink Charging Co. (NASDAQ: BLNK) shares climbed 31.68 percent to close at $7.19 on Wednesday. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares gained 24.15 percent to close at $3.29. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    21Vianet Group, Inc. (NASDAQ: VNET) shares surged 24 percent to close at $6.82.
    Check-Cap Ltd. (NASDAQ: CHEK) gained 20.25 percent to close at $4.87.
    HUYA Inc. (NYSE: HUYA) shares surged 18.42 percent to close at $22.50
    Abaxis, Inc. (NASDAQ: ABAX) rose 16.15 percent to close at $83.34. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    Pain Therapeutics, Inc. (NASDAQ: PTIE) shares jumped 16.07 percent to close at $10.62.
    Bilibili Inc. (NASDAQ: BILI) rose 16.04 percent to close at $14.11.
    Gemphire Therapeutics Inc. (NASDAQ: GEMP) gained 14.88 percent to close at $6.33.
    Phoenix New Media Limited (NYSE: FENG) rose 13.96 percent to close at $5.55.
    Daqo New Energy Corp. (NYSE: DQ) jumped 13.88 percent to close at $67.27 on Wednesday.
    Sea Limited (NYSE: SE) jumped 12.59 percent to close at $11.98 after reporting Q1 results.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 12.01 percent to close at $5.13.
    Ascena Retail Group, Inc. (NASDAQ: ASNA) gained 11.93 percent to close at $3.19.
    Boot Barn Holdings, Inc. (NYSE: BOOT) climbed 11.66 percent to close at $24.52 on Wednesday after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Macy's, Inc. (NYSE: M) rose 10.83 percent to close at $33.17 after the company reported stronger-than-expected results for its first quarter and lifted guidance.
    ChemoCentryx, Inc. (NASDAQ: CCXI) gained 9.36 percent to close at $12.50. Canaccord Genuity initiated coverage on ChemoCentryx with a Buy rating.
    Biolinerx Ltd/S ADR (NASDAQ: BLRX)

Top 10 Performing Stocks To Buy For 2019: Culp, Inc.(CFI)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Cofound.it (CURRENCY:CFI) traded down 2.1% against the U.S. dollar during the 24-hour period ending at 21:00 PM Eastern on May 12th. In the last week, Cofound.it has traded down 21% against the U.S. dollar. One Cofound.it token can currently be purchased for about $0.0769 or 0.00000911 BTC on major exchanges including Liqui, IDEX, HitBTC and Upbit. Cofound.it has a total market capitalization of $25.01 million and approximately $314,252.00 worth of Cofound.it was traded on exchanges in the last day.

Top 10 Performing Stocks To Buy For 2019: Sanofi(SNY)

Advisors’ Opinion:

  • [By Todd Campbell]

    When a brand new class of cholesterol-lowering drugs called PCSK9 inhibitors won Food and Drug Administration (FDA) approval in 2015, it was heralded as the biggest advance in battling heart disease since the invention of statins. The launch of PCSK9 inhibitors was accompanied by billion-dollar-plus predictions for sales. However, revenue has fallen far shy of blockbuster status, leaving drugmakers Amgen Inc. (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), and Sanofi SA (NYSE:SNY) in the lurch.

  • [By Cory Renauer]

    Sanofi (NYSE:SNY) andRegeneron (NASDAQ:REGN) launched a cholesterol-lowering treatment in 2015 that could be a big problem for bempedoic acid, even if its safety profile remains intact. Praluent is a remarkable drug that can turn stubborn liver cells into cholesterol sponges, but at an initial list price of around $14,000 per year, its launch was a huge disappointment.

  • [By Keith Speights]

    Alnylam’s partner, Sanofi (NYSE:SNY), is taking the lead on a phase 3 study of another experimental RNAi therapeutic,fitusiran, in treating hemophilia A and B. Sanofi now has global rights to the drug as a result of a restructuring of the two companies’ rare disease collaboration agreement signed in 2014. Alnylam stands to receive royalties between 15% and 30% of any future sales for fitusiran.

Top 10 Performing Stocks To Buy For 2019: S&W Seed Company(SANW)

Advisors’ Opinion:

  • [By Ethan Ryder]

    S&w Seed (NASDAQ:SANW) – Equities researchers at B. Riley decreased their Q3 2019 earnings per share (EPS) estimates for S&w Seed in a research note issued to investors on Thursday, May 10th. B. Riley analyst S. Sherbetchyan now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their previous forecast of $0.01. B. Riley has a “Buy” rating and a $5.50 price objective on the stock.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on S&w Seed (SANW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Performing Stocks To Buy For 2019: GTx Inc.(GTXI)

Advisors’ Opinion:

  • [By Chris Lange]

    GTx Inc. (NASDAQ: GTXI) will present additional data demonstrating duration of response following completion of treatment for its Phase 2 proof-of-concept clinical trial evaluating enobosarm 3 mg in postmenopausal women with stress urinary incontinence at the upcoming 2018 American Urological Association meeting on May 18.

Top 10 Performing Stocks To Buy For 2019: Simulations Plus, Inc.(SLP)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Simulations Plus (SLP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Simulations Plus (NASDAQ:SLP) shares hit a new 52-week high and low during mid-day trading on Monday . The company traded as low as $18.55 and last traded at $18.35, with a volume of 49668 shares changing hands. The stock had previously closed at $18.20.

  • [By Ethan Ryder]

    Simulations Plus (NASDAQ:SLP) was upgraded by equities research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued on Monday.

Top 10 Performing Stocks To Buy For 2019: ENERGY TRANSFER PARTNERS(ETP)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    While ONEOK is one of the largest energy infrastructure companies in the country, one thing others have that it lacks is an export terminal. An analyst on the call pointed this out and asked how aggressively the company was pursuing exports given that rivals Enterprise Products Partners (NYSE:EPD) and Energy Transfer Partners (NYSE:ETP) recently signed joint ventures (JVs) to build new export terminals. In Enterprise’s case, it signed a JV to construct an ethylene export facility to move the key petrochemical to market centers. Meanwhile, Energy Transfer secured a JV to build an ethane export facility. Both projects should start up in 2020 and supply thesecompanies with steady cash flow for years via long-term, fee-based contracts.

  • [By Matthew DiLallo]

    The market has pummeled master limited partnerships (MLPs) over the past few years due to the impact the oil market downturn had on their operations and business model. Among the hardest-hit have been oil pipeline MLP Plains All American Pipeline (NYSE:PAA) and gas pipeline giant Energy Transfer Partners (NYSE:ETP), both of which have lost more than half their value over the last three years. That persistent slump comes even though their turnaround strategies are beginning to gain steam. While these companies still have some work to do before they’re back on solid ground, both could deliver significant returns as they complete their plans and the oil market continues rebounding over the next few years. That upside potential makes them compelling options for investors with a higher tolerance for risk.

  • [By ]

    Energy Transfer Partners LP (NYSE: ETP)
    Formerly Sunoco Logistics Partners, ETP focuses on transport and storage of crude oil, refined products, and natural gas liquids (NGLs). Headquartered in Texas (where else?), ETP manages a portfolio that includes more than 71,000 miles of pipeline as well as marketing services.

  • [By Steve Symington, John Bromels, and Keith Noonan]

    So we asked three Motley Fool contributors exactly that. Read on to learn why they like Retail Opportunity Investments (NASDAQ:ROIC), Energy Transfer Partners (NYSE:ETP), and GameStop (NYSE:GME).

  • [By Matthew DiLallo]

    After facing several challenges over the past few years, Energy Transfer Partners(NYSE:ETP) has turned things around, which was evident in its first-quarter results. Earnings and cash flow jumped thanks to recent project completions, while a string of asset sales and other strategic financing initiatives have helped bolster its balance sheet and ability to fund additional growth projects. While the company still has some work to do before all its issues are in the rearview mirror, it’s certainly heading in the right direction.

  • [By Danny Vena, John Bromels, and Demitrios Kalogeropoulos]

    As appetizing as that dividend is, there are other companies that offer an even tastier yield. With that in mind, we asked three Motley Fool investors to choose top companies that would provide investors an even more generous payout. They offered compelling arguments for National Retail Properties (NYSE:NNN), Energy Transfer Partners, LLP (NYSE:ETP), and DSW Inc. (NYSE:DSW).

Best Blue Chip Stocks To Invest In Right Now

U.S. stocks opened firmly higher on Thursday, extending a late-session rally from the prior session, as investors dialed back on fears that a trade spat between the U.S. and China will materialize.

The major equity indexes staged a big turnaround Wednesday after opening sharply lower, as traders struggled to interpret the possible impact of the trade standoff on U.S. corporate earnings and growth.

What are main benchmarks doing?

Dow Jones Industrial Average
DJIA, +0.69%
rise rose about 150 points, or 0.6%, to 24,410. Blue chips are attempting to mark their first three-session win streak since the three-day period ended Feb. 26, according to FactSet data. The S&P 500 index
SPX, +0.46%
was up 12 points, or 0.4%, to 2,656, led by a 1.2% gain in energy and a 0.8% climb in technology stocks.

Best Blue Chip Stocks To Invest In Right Now: GTx Inc.(GTXI)

Advisors’ Opinion:

  • [By Chris Lange]

    GTx Inc. (NASDAQ: GTXI) will present additional data demonstrating duration of response following completion of treatment for its Phase 2 proof-of-concept clinical trial evaluating enobosarm 3 mg in postmenopausal women with stress urinary incontinence at the upcoming 2018 American Urological Association meeting on May 18.

Best Blue Chip Stocks To Invest In Right Now: TrueBlue Inc.(TBI)

Advisors’ Opinion:

  • [By Logan Wallace]

    Trueblue (NYSE: TBI) is one of 23 public companies in the “Help supply services” industry, but how does it contrast to its rivals? We will compare Trueblue to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, earnings and risk.

Best Blue Chip Stocks To Invest In Right Now: Amtech Systems Inc.(ASYS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    ValuEngine cut shares of Amtech Systems (NASDAQ:ASYS) from a hold rating to a sell rating in a research note published on Wednesday morning.

    Separately, Zacks Investment Research raised Amtech Systems from a sell rating to a hold rating in a research report on Monday, April 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $14.88.

  • [By Lisa Levin] Gainers
    The Trade Desk, Inc. (NASDAQ: TTD) jumped 36.2 percent to $71.82 after the company reported upbeat results for its first quarter. The company also issued strong second-quarter and FY18 sales guidance.
    WideOpenWest, Inc. (NYSE: WOW) jumped 30.4 percent to $8.80 after the company reported Q1 results.
    MoSys, Inc. (NASDAQ: MOSY) shares surged 28.6 percent to $1.9541 after the company reported better-than-expected Q1 results and issued strong Q2 forecast.
    Boxlight Corporation (NASDAQ: BOXL) gained 24 percent to $6.39.
    Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares gained 19.1 percent to $24.60. Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced that the Endocrinologic and Metabolic Drugs Advisory Committee, which met to discuss the safety and efficacy of subcutaneously injected volanesoren solution for patients with familial chylomicronemia syndrome, voted 12-8 to support its approval.
    Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) shares rose 17 percent to $10.31 after reporting Q3 results.
    ArcBest Corporation (NASDAQ: ARCB) gained 16.8 percent to $43.1457 after reporting upbeat quarterly earnings.
    Amtech Systems, Inc. (NASDAQ: ASYS) rose 16.2 percent to $8.60. Amtech posted Q2 earnings of $0.19 per share on sales of $32.783 million.
    Identiv, Inc (NASDAQ: INVE) surged 14.4 percent to $3.8450 following Q1 results.
    Omeros Corporation (NASDAQ: OMER) shares rose 14.3 percent to $18.43 following Q1 results.
    VivoPower International PLC (NASDAQ: VVPR) gained 11.5 percent to $2.71.
    Intersections Inc. (NASDAQ: INTX) gained 11.4 percent to $2.55 after reporting Q1 results.
    Noodles & Company (NASDAQ: NDLS) shares rose 10.9 percent to $8.65 following Q1 results.
    Voyager Therapeutics, Inc. (NASDAQ: VYGR) climbed 10.6 percent to $18.54 following Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) rose 10.4 percent to $5.739.
    Immersion Corporation (NASDAQ: IMMR) gained 9.6 percent to $12.69

Best Blue Chip Stocks To Invest In Right Now: National Commerce Corporation(NCOM)

Advisors’ Opinion:

  • [By Logan Wallace]

    National Commerce (NASDAQ:NCOM) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Friday.

Best Blue Chip Stocks To Invest In Right Now: Stag Industrial, Inc.(STAG)

Advisors’ Opinion:

  • [By Lee Jackson]

    STAG Industrial Inc. (NYSE: STAG) offers investors a 5.8% yield. Share recently traded hands at $24.35 apiece, in a 52-week range of $22.42 to $28.85. The consensus target price is $27.73.

Best Blue Chip Stocks To Invest In Right Now: CEVA, Inc.(CEVA)

Advisors’ Opinion:

  • [By Logan Wallace]

    CEVA (NASDAQ:CEVA) had its price objective decreased by Roth Capital to $44.00 in a research note released on Wednesday morning. Roth Capital currently has a buy rating on the semiconductor company’s stock.

  • [By Stephan Byrd]

    COPYRIGHT VIOLATION WARNING: “CEVA (CEVA) Rating Increased to Hold at BidaskClub” was posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3370458/ceva-ceva-rating-increased-to-hold-at-bidaskclub.html.

  • [By Lisa Levin]

    CEVA, Inc. (NASDAQ: CEVA) was down, falling around 12 percent to $30.25 after the company posted weaker-than-expected Q1 profit.

    Commodities

Top 5 Performing Stocks To Watch Right Now

It’s time to see if SeaWorld Entertainment (NYSE:SEAS) can earn a treat by performing a fancy trick above water. The struggling theme park operator has a media event slated for Thursday morning at its flagship SeaWorld Orlando park. Speculation centers around the unveiling of a new sea-rescue-themed attraction, but some brand bashers hope that SeaWorld will be taking additional steps to wean itself from live marine-life entertainment.

Let’s not get too ahead of ourselves on the latter. The timing of the media fete may coincide with Takara — SeaWorld Antonio’s pregnant orca — being ready to give birth later this month, but there’s a reason why this announcement is being made in Florida instead of Texas. SeaWorld is billing Takara’s birthing process as the last killer whale born at any SeaWorld park, a slick move to distance itself from the notoriety caused by the documentary Blackfish, but Thursday’s move will probably be more about a new ride coming to its most visited park next year.

Top 5 Performing Stocks To Watch Right Now: GTx Inc.(GTXI)

Advisors’ Opinion:

  • [By Roberto Pedone]

    One biopharmaceutical player that’s rapidly moving within range of triggering a major breakout trade is GTx (GTXI), which is dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical condition. This stock has been hammered by the bears so far in 2013, with shares off sharply by 53%.

    If you look at the chart for GTx, you’ll notice that this stock recently gapped down sharply from over $4 to below $1.50 a share with heavy downside volume. Following that gap down, shares of GTXI have rebounded sharply and started to uptrend, with the stock moving higher from its low of $1.31 to its recent high of $1.96 a share. During that move, shares of GTXI have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GTXI within range of triggering a major breakout trade.

    Traders should now look for long-biased trades in GTXI if it manages to break out above some near-term overhead resistance at $1.96 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.35 million shares. If that breakout triggers soon, then GTXI will set up to re-fill some of its previous gap down zone from August that started just above $4 a share. Some possible upside targets if GTXI gets into that gap with volume are $2.50 to $3 a share, or possibly even $3.50 a share.

    Traders can look to buy GTXI off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.50 a share. One can also buy GTXI off strength once it takes out $1.96 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 5 Performing Stocks To Watch Right Now: Franklin Covey Company(FC)

Advisors’ Opinion:

  • [By Monica Gerson]

     

    Darden Restaurants, Inc. (NYSE: DRI) is estimated to report its quarterly earnings at $1.08 per share on revenue of $1.81 billion. ConAgra Foods Inc (NYSE: CAG) is expected to report its quarterly earnings at $0.52 per share on revenue of $2.89 billion. Paychex, Inc. (NASDAQ: PAYX) is projected to report its quarterly earnings at $0.49 per share on revenue of $751.52 million. Micron Technology, Inc. (NASDAQ: MU) is expected to post a quarterly loss at $0.09 per share on revenue of $2.95 billion. McCormick & Company, Incorporated (NYSE: MKC) is estimated to report its quarterly earnings at $0.74 per share on revenue of $1.06 billion. Constellation Brands, Inc. (NYSE: STZ) is expected to report its quarterly earnings at $1.51 per share. Schnitzer Steel Industries, Inc. (NASDAQ: SCHN) is estimated to report its quarterly earnings at $0.18 per share on revenue of $356.41 million. Franklin Covey Co. (NYSE: FC) is expected to post its quarterly earnings at $0.08 per share on revenue of $49.89 million. Lindsay Corporation (NYSE: LNN) is projected to report its quarterly earnings at $0.99 per share on revenue of $148.43 million.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Top 5 Performing Stocks To Watch Right Now: BioAmber Inc.(BIOA)

Advisors’ Opinion:

  • [By Markus Aarnio]

    BioAmber (BIOA) is a sustainable chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products.

  • [By Maxx Chatsko]

    While companies with lower-priced shares are often riskier than those with higher prices, some companies trading under $5 per share have intriguing potential. Investors searching for overlooked growth opportunities should consider industrial biotech BioAmber (NYSE:BIOA), pharmaceutical services company Codexis (NASDAQ:CDXS), and one-trick-pony biopharma Keryx Biopharmaceuticals (NASDAQ:KERX).

  • [By Paul Ausick]

    BioAmber Inc. (NYSE: BIOA) dropped nearly 29% Friday to post a new 52-week low of $2.24 after closing Thursday at $3.14. Volume of more than 1.5 million shares was about 6 times the daily average of around 240,000. The company’s annual report, filed on Thursday with its quarterly results, included a “going concern” statement from the company’s independent auditing firm.

  • [By Lisa Levin]

    Bioamber Inc (NYSE: BIOA) shares dropped 19 percent to $2.55. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.

Top 5 Performing Stocks To Watch Right Now: Franklin Resources, Inc.(BEN)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Franklin Resources (BEN) : “I’d rather see you in Morgan Stanley (MS) or E*TRADE Financial (ETFC) .”

    Kinder Morgan (KMI) : “They are OK now, but there are better ones.”

  • [By Craig Jones]

    Jim Strugger recommended on Bloomberg Markets a long position in Franklin Resources, Inc. (NYSE: BEN).

    He said the company is in the assets management sector and he added that the market is probably getting into the period of higher dispersion, which is usually favorable for active managers. Speaking on the positive catalysts for the stock, Strugger said Franklin Resources is going to benefit from the cash repatriation.

Top 5 Performing Stocks To Watch Right Now: Tupperware Brands Corporation(TUP)

Advisors’ Opinion:

  • [By George Budwell, Rich Smith, and Neha Chamaria]

    Keeping with this theme, our Foolish contributors think that Pfizer (NYSE:PFE),Sherwin-Williams (NYSE:SHW), andTupperware Brands (NYSE:TUP)are three large-cap dividend stocks that prove beyond a doubt that boring is beautiful when it comes to creating wealth.

  • [By Seth McNew]

    Shares ofTupperware Brands(NYSE:TUP), the classic food-storage brand that has evolved to becomemore than meets the eye, spiked as much as 12% today, after the company reported better-than-expected Q1 earnings and set positive guidance for 2017.

best stocks to buy now

California doesn’t like Trump, but sure does like tax increases. At around the same time as President Trump was being elected, California was increasing state income taxes again. The state’s high 13.3% California tax are only temporary though, just through 2030! Of course, that was back in November. It must be time for another tax hike. The latest is a move by the Golden State to tax estates, even if the feds do not.

If the federal estate tax law is repealed by President Trump and Congress, estates in California will still pay. A bill was introduced by state Sen. Scott Wiener (D-San Francisco), asking voters to keep the estate tax after all. The proposal would have to go to voters. As Mr. Wiener put it:

If Donald Trump and congressional Republicans are hell-bent on cutting taxes for our wealthiest residents, we should counter-balance those tax cuts by recapturing the lost funds and investing them here at home in our schools, our healthcare system, and our roads and public transportation systems.”

best stocks to buy now: MDC Partners Inc.(MDCA)

Advisors’ Opinion:

  • [By Lisa Levin]

    MDC Partners Inc (NASDAQ: MDCA) shares dropped 60 percent to $3.38. MDC Partners reported a Q3 loss of $0.64 per share on revenue of $349.3 million.

  • [By Lisa Levin]

    Shares of MDC Partners Inc (NASDAQ: MDCA) were down 31 percent to $12.52 after the company posted downbeat quarterly results and lowered its FY16 sales outlook.

best stocks to buy now: SORL Auto Parts Inc.(SORL)

Advisors’ Opinion:

  • [By Monica Gerson]

    Sorl Auto Parts, Inc. (NASDAQ: SORL) is expected to post its quarterly earnings at $0.20 per share on revenue of $55.35 million.

    Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is projected to post a quarterly loss at $0.18 per share on revenue of $10.25 million.

  • [By Lisa Levin]

    Sorl Auto Parts, Inc. (NASDAQ: SORL) was down, falling around 8 percent to $3.68. Greenridge Global downgraded SORL Auto Parts from Buy to Hold.

best stocks to buy now: GTx Inc.(GTXI)

Advisors’ Opinion:

  • [By Roberto Pedone]

    One biopharmaceutical player that’s rapidly moving within range of triggering a major breakout trade is GTx (GTXI), which is dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical condition. This stock has been hammered by the bears so far in 2013, with shares off sharply by 53%.

    If you look at the chart for GTx, you’ll notice that this stock recently gapped down sharply from over $4 to below $1.50 a share with heavy downside volume. Following that gap down, shares of GTXI have rebounded sharply and started to uptrend, with the stock moving higher from its low of $1.31 to its recent high of $1.96 a share. During that move, shares of GTXI have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GTXI within range of triggering a major breakout trade.

    Traders should now look for long-biased trades in GTXI if it manages to break out above some near-term overhead resistance at $1.96 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.35 million shares. If that breakout triggers soon, then GTXI will set up to re-fill some of its previous gap down zone from August that started just above $4 a share. Some possible upside targets if GTXI gets into that gap with volume are $2.50 to $3 a share, or possibly even $3.50 a share.

    Traders can look to buy GTXI off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.50 a share. One can also buy GTXI off strength once it takes out $1.96 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

best stocks to buy now: Aurora Cannabis Inc. (ACBFF)

Advisors’ Opinion:

  • [By Keith Speights]

    As increasingly more marijuana growers entered the market and more states allowed residents to legally grow marijuana, cannabis prices dropped throughout 2016. Wholesale marijuana prices late in the year were roughly half the levels of 12 months earlier. Will this trend continue — and possibly hurt leading marijuana stocks including Aphria (NASDAQOTH:APHQF),Aurora Cannabis (NASDAQOTH:ACBFF), Medical Marijuana,Inc.(NASDAQOTH:MJNA), and even GW Pharmaceuticals (NASDAQ:GWPH) in the process?

  • [By SEEKINGALPHA.COM]

    This article is for those who are hopeful of the long-term view and want to get in ahead of time. This article will compare the three front-runners of the Canadian cannabis industry, Canopy Growth Corp. (OTCPK:TWMJF), Aphria (NYSE:APH), and Aurora (OTCQX:ACBFF). Although these companies will soon have to prove themselves in a new environment, there is plenty to study right now. We will be comparing revenue growth, production capacity, valuations, and then making financial projections. The result will be a recommendation of Aurora followed by Canopy. Again this article is meant to compare competitors. The industry has the potential to be a 22.6B industry but the thesis for investing in Canadian cannabis is a separate topic and I encourage you to consider the risks.

  • [By SEEKINGALPHA.COM]

    President Trump has threatened to increase enforcement of federal cannabis laws. One might think that this will have a negative impact on marijuana and marijuana related stocks like Aurora Cannabis (OTCQB:ACBFF), General Cannabis (OTCQB:CANN), Americann (OTCQX:ACAN), and MassRoots (OTCQB:MSRT), and if implemented it probably would be devastating, both to publicly traded marijuana companies, and to local companies in regions that have legalized pot.

Top Safest Stocks To Invest In 2017

There are definitely some transformational factors currently working in favor of this Top Pick, such as increasing cashless trends and a favorable regulatory environment, notes Bryan Perry, editor of Cash Machine.

The ability of PayPal (PYPL) to strike big deals while delivering outsized growth versus peers makes this a choice stock pick for 2017 and well beyond.

Though shares of PayPal have been range bound for the past ten months, the company has been performing strongly in global payments, both online and mobile. The company ended the third quarter with 192 million active customer accounts.

Partnership and mobile centrism were PayPal’s top priorities. The company’s ongoing strategic partnerships with Visa (V), MasterCard (MA) and Citigroup (C) offer great flexibility and choice to consumers and businesses alike. 

Partnerships with Facebook (FB), Apple (AAPL), and Alibaba (BABA) are also delivering positive results that are all in the early stages of much broader expansion. Big deals with big players spell big top and bottom line growth.

Top Safest Stocks To Invest In 2017: GTx Inc.(GTXI)

Advisors’ Opinion:

  • [By Roberto Pedone]

    One biopharmaceutical player that’s rapidly moving within range of triggering a major breakout trade is GTx (GTXI), which is dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical condition. This stock has been hammered by the bears so far in 2013, with shares off sharply by 53%.

    If you look at the chart for GTx, you’ll notice that this stock recently gapped down sharply from over $4 to below $1.50 a share with heavy downside volume. Following that gap down, shares of GTXI have rebounded sharply and started to uptrend, with the stock moving higher from its low of $1.31 to its recent high of $1.96 a share. During that move, shares of GTXI have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GTXI within range of triggering a major breakout trade.

    Traders should now look for long-biased trades in GTXI if it manages to break out above some near-term overhead resistance at $1.96 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.35 million shares. If that breakout triggers soon, then GTXI will set up to re-fill some of its previous gap down zone from August that started just above $4 a share. Some possible upside targets if GTXI gets into that gap with volume are $2.50 to $3 a share, or possibly even $3.50 a share.

    Traders can look to buy GTXI off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.50 a share. One can also buy GTXI off strength once it takes out $1.96 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top Safest Stocks To Invest In 2017: MetLife, Inc.(MET)

Advisors’ Opinion:

  • [By Matthew Frankel]

    MetLife (NYSE:MET) is the largest U.S. life insurer, with one of the strongest brand names in the insurance industry and an excellent distribution network. The company has a variety of life insurance offerings, and about one-third of its earnings come from Latin America, Asia, and other foreign markets, which are expected to be big drivers of growth going forward.

Top Safest Stocks To Invest In 2017: Unifi, Inc.(UFI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Unifi, Inc. (NYSE: UFI) shares were also up, gaining 18 percent to $26.92 as the company announced Q3 earnings of $0.56 per share on revenue of $161.3 million.

Top Safest Stocks To Invest In 2017: Packaging Corporation of America(PKG)

Advisors’ Opinion:

  • [By Paul Ausick]

    Stocks on the move: Boise Inc. (NYSE: BZ) is up 26% at $12.55 following the companys acquisition by Packaging Corporation of America Inc. (NYSE: PKG) for $12.55 a share ($1.28 billion). Omeros Corp. (NASDAQ: OMER) is up 68.2% at $8.56 following an analyst upgrade. Northern Dynasty Minerals Ltd. (NYSEArca: NAK) is down 33.3% at $1.48 following an announcement from Anglo American plc that it was withdrawing from a massive copper mining project in Alaska.

  • [By Ben Levisohn]

    Packaging Corp. of America(PKG) has jumped 6.3% to $57.99 after it said it would buy Boise (BZ) for $1.28 billion. Boise has gained 26% to $12.55.

  • [By Daniela Pylypczak]

    Jefferies announced on Monday that it has upgraded Packaging Corp of America (PKG) from “Hold” to “Buy.”

    The firm also raised PKG’s price target from $49.00 to $70.00. Jefferies analystPhilip Ng also gave the companybull-case scenario target of $88. The upgrade comes after the firm announced earlier today that it has agreed to purchase all outstanding shares of Boise Inc. (BZ)for $1.995 billion. Analyst Ng believes the new acquisition will result in an attractive multiple.

    Packaging Corp of America shares rallied 9.73% during Monday’s session. Year-to-date, the stock is up 39.87%.

Top Safest Stocks To Invest In 2017: Biotricity (BTCY)

Advisors’ Opinion:

  • [By Matthew Briar]

    Biotricity Inc (OTCMKTS:BTCY) announced on Tuesday morning it was teaming up with Global to Local (G2L) to develop remote monitoring solutions that not only work, but serve the underserved (medically speaking) community. This partnership is of particular interest to current and would-be BTCY investors, as it will likely validate the crux of the work the company has done thus far.

    Biotricity is the developer of two different though related technologies. One is called bioflux, and the other is called biolife. Both are heart-monitoring devices… the former for use by caregivers in a clinical setting, while the latter is for use by individuals outside of a clinical setting. Neither is on the market yet, but both are projected to be on the market next year. The company recently filed a 510k request with the FDA for its bioflux technology (the 510k path is for medical devices rather than drugs, and as such doesn’t require a lot of regulatory deliberation), and has heard back from the FDA about a key part of the device already – it got the green light. Another arm of the FDA must look at other aspects of the device.

    The technology is unique, in that it not only provides stunningly accurate detailed information about a patient’s heart function, but it constantly feeds that data – remotely – to a caregiver and monitor that can make good use of that data. In August the company announced AT&T Inc. (NYSE:T) would be handling the wireless (cellular) connectivity between clinics and patients’ bioflux devices.

    It’s a breakthrough, for many reasons, not the least of which is that remote monitoring lowers overall healthcare costs for those patients, and ultimately, for insurers.

    The hardware is not yet available on a commercial basis, but it is being tested in a clinical setting. The Global to Local partnership will be another field test of sorts, validating the work Biotricity has performed on the R&D front.

    The organization says

  • [By James E. Brumley]

    While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.

    These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.

    One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.

    It’s not been a smooth beginning. however.

    While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.

    Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.

    On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.

    Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an

  • [By Matthew Briar]

    In October, medical technology developer Biotricity Inc. (OTCMKTS:BTCY) announced part of its heart-monitoring hardware received the necessary 501k clearance from the Food & Drug Administration. It was a not-so-subtle reminder that the company is nearing the end of the R&D journey with its bioflux device, which provides caregivers round-the-clock monitoring of a heart patient’s vital stats. BTCY could have the device on the market within a matter of weeks, putting the organization into a multi-billion dollar market with a platform like no other.

    And yet, heart-monitoring is only going to be a part of what the company does.

    Another news later that same month was a not-so-subtle reminder…. Biotricity Inc. is already eyeing the entry into other markets aside from the cardiac market that would benefit from remote monitoring.

    One has to back-track to the September 29th press release to set the stage. That’s when the company announced it would take the same basic remote-monitoring technology and apply it to fetal monitoring and sleep apnea, at least. The way the PR read left open the possibility to even more medically-related uses.

    For some it may have been a read-it-and-forget-it affair. Lots of companies announce their intentions, and then get around to doing it whenever they feel like it, IF they feel like it. Biotricity wasn’t just blowing smoke though. In October the company announced that its primary development partner — the University of Calgary — and it laid out specific plans to create ‘remote monitoring mobile devices in a number of clinical settings, including peri-operative medicine, maternal/fetal medicine and acute and chronic care medicine in order to facilitate the application of “smart” medical grade wearables to the hospital and out-patient settings.’

    This second mention of the idea suggests it’s going to happen sooner than later, even as the company continues to push bioflux to

  • [By Peter Graham]

    Sandhill.com recently interviewed the chairman, CEO and founder Waqaas Al-Siddiq small cap wearables stock Biotricity (OTCQB: BTCY) about how wearables benefit patients, integrate into healthcare systems and improve treatment compliance as well as how the cloud and the Internet of Things impact the medical wearables space. biotricitys is a medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricitys R&D focuses on the preventative healthcare market, with a vision of putting health management into the hands of the individual by supporting the self-management of critical and chronic conditions.

  • [By Peter Graham]

    On the other hand, small cap wearables stock Biotricity (OTCQB: BTCY)is a different wearables play as theCompanys mission is to revolutionize chronic care management by developing innovative solutions that bridge the gap between diagnostic care and disease management. A medical technology company, Biotricity is focused on delivering innovative, remote biometric monitoring solutions to the healthcare and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricitys R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The Company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system.

  • [By Bryan Murphy]

    As much progress as the remote medical monitoring device market has made in recent years, we’ve still only scratched the surface. The surface has been scratched though. The Dexcom G5 mobile glucose monitor from DexCom, Inc. (NASDAQ:DXCM) is one impressive example. Arguably the first and best entry in the race, DexCom has sent a clear message that consumers and caregivers are ready for a functional device that takes care of itself.

    At the other end of the spectrum is a recent round of products that are less clinical in nature, and more broad-usage friendly. Devices like the Apple Inc. (NASDAQ:AAPL) watch and the Fitbit Inc (NYSE:FIT) line of products are both capable of monitoring heart rates and activity. On the other, neither does it all that well… not like one would expect in a clinical setting. Fitbit has run into a headwind of legal and reputational trouble since it’s been verified that its trackers aren’t all that accurate; Apple avoided such trouble largely because few consumers ever viewed its watches as medical-grade hardware.

    The gap between the Dexcom G5 and the Fitbit fitness trackers, however, is where real opportunity lies. See, the entries to date have proven there is a market for mobile medical devices , but have also proven they have to work as well as the equipment one might expect to find in a doctor’s office or in a hospital.

    It’s this subtle nuance that puts a young company called Biotricity Inc. (OTCMKTS:BTCY) in the spotlight, as it has melded mobile monitoring and quality monitoring, and is now in the midst of making sure they’re marketable… not just to consumers, but to insurance companies (which tend to pay a lot more than the average consumer does). Fitbit missed the mark on both fronts.

    Biotricity is working two different but similar pieces of technology. One is called bioflux, for use by caregivers in a clinical setting, and the other is biolife individuals outside of a clinical setting. Neither is o